265 related articles for article (PubMed ID: 36528237)
1. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
[TBL] [Abstract][Full Text] [Related]
2. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
3. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
[TBL] [Abstract][Full Text] [Related]
4. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
5. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
6. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
[TBL] [Abstract][Full Text] [Related]
8. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
9. Training of computational algorithms to predict NAFLD activity score and fibrosis stage from liver histopathology slides.
Qu H; Minacapelli CD; Tait C; Gupta K; Bhurwal A; Catalano C; Dafalla R; Metaxas D; Rustgi VK
Comput Methods Programs Biomed; 2021 Aug; 207():106153. PubMed ID: 34020377
[TBL] [Abstract][Full Text] [Related]
10. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL
J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973
[TBL] [Abstract][Full Text] [Related]
11. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
[TBL] [Abstract][Full Text] [Related]
12. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
Vali Y; Lee J; Boursier J; Petta S; Wonders K; Tiniakos D; Bedossa P; Geier A; Francque S; Allison M; Papatheodoridis G; Cortez-Pinto H; Pais R; Dufour JF; Leeming DJ; Harrison SA; Chen Y; Cobbold JF; Pavlides M; Holleboom AG; Yki-Jarvinen H; Crespo J; Karsdal M; Ostroff R; Zafarmand MH; Torstenson R; Duffin K; Yunis C; Brass C; Ekstedt M; Aithal GP; Schattenberg JM; Bugianesi E; Romero-Gomez M; Ratziu V; Anstee QM; Bossuyt PM;
Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):714-725. PubMed ID: 36958367
[TBL] [Abstract][Full Text] [Related]
14. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
15. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
Bril F; Barb D; Lomonaco R; Lai J; Cusi K
J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
17. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
[TBL] [Abstract][Full Text] [Related]
18. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
Parikh P; Patel J; Ingle M; Sawant P
Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
[TBL] [Abstract][Full Text] [Related]
19. qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Liu F; Goh GB; Tiniakos D; Wee A; Leow WQ; Zhao JM; Rao HY; Wang XX; Wang Q; Wan WK; Lim KH; Romero-Gomez M; Petta S; Bugianesi E; Tan CK; Harrison SA; Anstee QM; Chang PJ; Wei L
Hepatology; 2020 Jun; 71(6):1953-1966. PubMed ID: 31600834
[TBL] [Abstract][Full Text] [Related]
20. Pathology of non-alcoholic fatty liver disease.
Bedossa P
Liver Int; 2017 Jan; 37 Suppl 1():85-89. PubMed ID: 28052629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
